ArticleParasite (Paris, France)2019
Identification of newly developed advanced schistosomiasis with MALDI-TOF mass spectrometry and ClinProTools analysis.
Article in Parasite (Paris, France), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Accurately IdentifyingDiagnostics (Basel, Switzerland) · 2026Article
- MiR-383-5p promotes schistosomiasis-induced liver fibrosis by targeting peroxiredoxin-3.Parasites & vectors · 2025Article
- Metabolomics analysis of patients with Schistosoma japonicum infection based on UPLC-MS method.Parasites & vectors · 2024Article
- Dysregulated Glucuronidation of Bilirubin Exacerbates Liver Inflammation and Fibrosis in Schistosomiasis Japonica through the NF-κB Signaling Pathway.Pathogens (Basel, Switzerland) · 2024Article
- MALDI-TOF: A new tool for the identification of Schistosoma cercariae and detection of hybrids.PLoS neglected tropical diseases · 2023Article
- Recent Advances and Potential Future Applications of MALDI-TOF Mass Spectrometry for Identification of Helminths.Diagnostics (Basel, Switzerland) · 2022Review
- Rapid Peak Alignment for MALDI-TOF Lipid Analysis.Journal of bioanalytical methods and techniques · 2021Article
- Analysis of Intestinal Microflora and Metabolites From Mice With DSS-Induced IBD Treated WithFrontiers in cell and developmental biology · 2021Article
- MiR-130a-3p Alleviates Liver Fibrosis by Suppressing HSCs Activation and Skewing Macrophage to Ly6CFrontiers in immunology · 2021Article
- Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway.Parasites & vectors · 2020Article
- UHPLC-MS-Based Metabolomics Analysis Reveals the Process of Schistosomiasis in Mice.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cases of newly developed advanced schistosomiasis (NDAS) have occurred in areas where schistosomiasis transmission has been blocked for more than 25 years. The causes and pathogenesis of NDAS are still unknown. Diagnosis of NDAS relies on historical investigation and clinical symptoms, such as liver fibrosis, hepatic ascites and abnormal biochemical indexes in serum. It is important but difficult at this stage to develop a new tool for early screening and rapid diagnosis. In this study, serum peptides from thirty patients with NDAS and thirty healthy controls were captured with weak cation exchange magnetic beads, and subjected to MALDI-TOF mass spectrometry and ClinProTools analysis. Eleven peaks with m/z 924, 2661, 2953, 2991, 3241, 3884, 5337, 5905, 5943, 7766 and 9289 were decreased and three peaks with m/z 1945, 2082 and 4282 were increased in the NDAS group. The proteomic detection pattern (PDP) was established with 14 different peptide peaks, and its sensitivity and specificity were investigated with a blind test. The peptide mass fingerprints of sera from 50 NDAS patients and 100 healthy controls were double-blind subjected to the PDP method, and 50 patients and 92 healthy controls were classified as NDAS and healthy separately, which showed 100% sensitivity and 92% specificity. Our results showed that the PDP could be a new and useful method to detect NDAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.